# Study of QLS5308 in Patients With Advanced Solid Tumors

> **NCT07462442** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 192 (estimated)

## Conditions studied

- Metastatic Solid Tumors

## Interventions

- **DRUG:** QLS5308 IV infusion

## Key facts

- **NCT ID:** NCT07462442
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-28
- **Primary completion:** 2027-06
- **Final completion:** 2031-08
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07462442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07462442, "Study of QLS5308 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07462442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*